Clarient has launched a new gene expression diagnostic for prostate cancer, the Insight Dx Prostate Profile (Insight). The test, developed in conjunction with Health Discovery Corp., uses expression values from four genes […]
AngioDynamics: No Growth Expected in 2009
It’s been a roller coaster of a year for AngioDynamics. In the past, I’ve professed my high opinion of the company. I still like ANGO and I think it’s fairly valued, but […]
A Long Time Coming: Electro-Optical Sciences to Announce MelaFind Trial Results
Irvington-NY based Electro-Optical Sciences (EOS), developer of The MelaFind System, a handheld imaging device that detects melanomas at an early stage, announced last week that its pivotal trial sites have closed: all […]
OneMedForum 2009: Panels and Speakers
The OneMedPlace finance conference for emerging med tech companies, the OneMedForum, will be held January 13-14 in San Francisco. Click here to learn more. Our featured panelists and speakers will be recognized […]
Mike Landess’ Battle with Prostate Cancer
A quick shout to Mike Landess, a Denver, CO newsman who this week released a half hour DVD special on prostate cancer (check out his blog). Mike was diagnosed with the disease […]
[Video Profile] Interview with Michael Fons, VP Corporate Development at Inovio Biomedical
Inovio Biomedical’s electroporation technology uses brief, controlled electrical pulses to increase cellular uptake of gene expression in DNA-based treatments; this enhances the potency of DNA-based immunotherapies against cancers and infectious diseases. Inovio […]
Trod Medical: FDA 510(k) Clearance for Encage
Trod Medical has received FDA 510(k) clearance for Encage, a minimally invasive technology for soft tissue ablation. The surgical system allows for precise percutaneous ablation of target tissue with well-defined margins, helping […]
Endocare and Galil Medical to Merge
Only months after Healthtronics withdrew its offer to acquire Endocare for $2.28 per share, Endocare and privately held Galil Medical have agreed to merge. The combined company will be focused on the […]
